Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
casdatifan + zimberelimab
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (for Casdatifan), Intravenous (for Zimberelimab; Dosed As 360mg Every 3 Weeks In Trials)
01
Overview
Casdatifan + zimberelimab is an investigational combination therapy under clinical development for advanced cancers, especially clear cell renal cell carcinoma (ccRCC). **Casdatifan** is a small molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α), a transcription factor involved in tumor progression and adaptation to hypoxic conditions. **Zimberelimab** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immunity. This combination aims to provide complementary anti-tumor effects by inhibiting tumor growth/metabolism and restoring immune-mediated cytotoxicity. The combination is primarily being investigated in patients who have progressed on prior immunotherapy[5][9].
- Other names
- casdatifan + zimberelimab
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on casdatifan + zimberelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on casdatifan + zimberelimab.